PL3706724T3 - Doustne kompozycje ryfamycyny sv - Google Patents

Doustne kompozycje ryfamycyny sv

Info

Publication number
PL3706724T3
PL3706724T3 PL18807426.4T PL18807426T PL3706724T3 PL 3706724 T3 PL3706724 T3 PL 3706724T3 PL 18807426 T PL18807426 T PL 18807426T PL 3706724 T3 PL3706724 T3 PL 3706724T3
Authority
PL
Poland
Prior art keywords
rifamicin
oral
compositions
rifamicin compositions
oral rifamicin
Prior art date
Application number
PL18807426.4T
Other languages
English (en)
Inventor
Luigi Moro
Luigi Maria Longo
Original Assignee
Cosmo Technologies Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd. filed Critical Cosmo Technologies Ltd.
Publication of PL3706724T3 publication Critical patent/PL3706724T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL18807426.4T 2017-11-10 2018-11-07 Doustne kompozycje ryfamycyny sv PL3706724T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762584226P 2017-11-10 2017-11-10
PCT/IB2018/058748 WO2019092614A1 (en) 2017-11-10 2018-11-07 Oral rifamycin sv compositions

Publications (1)

Publication Number Publication Date
PL3706724T3 true PL3706724T3 (pl) 2024-12-16

Family

ID=64426987

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18807426.4T PL3706724T3 (pl) 2017-11-10 2018-11-07 Doustne kompozycje ryfamycyny sv

Country Status (17)

Country Link
US (3) US11564883B2 (pl)
EP (3) EP3706724B1 (pl)
JP (2) JP2021502382A (pl)
KR (1) KR102747348B1 (pl)
CN (1) CN111328279B (pl)
AR (1) AR114140A1 (pl)
AU (1) AU2018364617B2 (pl)
BR (1) BR112020009171A2 (pl)
CA (1) CA3078900A1 (pl)
DK (1) DK3706724T3 (pl)
ES (1) ES2989706T3 (pl)
FI (1) FI3706724T3 (pl)
IL (1) IL274414B2 (pl)
MX (1) MX2020004706A (pl)
PL (1) PL3706724T3 (pl)
WO (1) WO2019092614A1 (pl)
ZA (1) ZA202002726B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022102198A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 内服固形剤
US20220280478A1 (en) * 2021-03-05 2022-09-08 Bausch Health Ireland, Limited Methods of using rifamycin sv for the treatment of sickle cell disease
JP2024536398A (ja) * 2021-10-05 2024-10-04 コスモ・テクノロジーズ・リミテツド 回腸嚢炎および遠位潰瘍性大腸炎を治療するためのリファマイシンのインサイチュゲル化浣腸剤
WO2025064599A1 (en) * 2023-09-19 2025-03-27 The United States Government As Represented By The Department Of Veterans Affairs Rifamycin composition for treating sarcopenia
WO2025157240A1 (zh) * 2024-01-26 2025-07-31 丹诺医药（苏州）股份有限公司 化合物用于制备治疗细菌代谢相关疾病的药物的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1046244B (zh) * 1999-06-14 2005-06-03 科斯默技术有限公司 控制释放与掩蔽味道的口服药物组合物
WO2005030173A1 (en) * 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
JP5061352B2 (ja) * 2006-01-04 2012-10-31 国立大学法人 東京医科歯科大学 肝臓疾患治療剤及び肝機能改善剤
DK2252148T3 (da) * 2008-02-26 2019-05-06 Salix Pharmaceuticals Ltd Fremgangsmåder til behandling af irritabel tarmsyndrom
CN102245615A (zh) * 2008-10-02 2011-11-16 萨利克斯药品有限公司 治疗肝性脑病的方法
US8741048B2 (en) 2011-08-30 2014-06-03 Brother Kogyo Kabushiki Kaisha Water-based ink for ink-jet recording and ink cartridge
CA2864065A1 (en) * 2012-02-13 2013-08-22 Cosmo Technologies Limited Method for treating intestinal diseases presenting at least one inflammatory component
KR102318025B1 (ko) * 2014-06-30 2021-10-27 샐릭스 파마슈티컬스 인코포레이티드 과민성 대장 증후군(ibs)의 재치료 방법
WO2017053885A1 (en) * 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same

Also Published As

Publication number Publication date
MX2020004706A (es) 2020-09-07
JP7651620B2 (ja) 2025-03-26
US11564883B2 (en) 2023-01-31
US20240398699A1 (en) 2024-12-05
CA3078900A1 (en) 2019-05-16
FI3706724T3 (fi) 2024-10-14
AU2018364617A1 (en) 2020-05-07
EP3706724A1 (en) 2020-09-16
IL274414A (en) 2020-06-30
IL274414B1 (en) 2024-04-01
RU2020119035A3 (pl) 2022-04-20
EP3706724B1 (en) 2024-09-11
JP2021502382A (ja) 2021-01-28
ZA202002726B (en) 2024-09-25
EP4431094A3 (en) 2024-11-20
US12036316B2 (en) 2024-07-16
CN111328279A (zh) 2020-06-23
WO2019092614A1 (en) 2019-05-16
US20230135346A1 (en) 2023-05-04
EP4438039A2 (en) 2024-10-02
US20200281850A1 (en) 2020-09-10
EP4438039A3 (en) 2024-12-04
AU2018364617B2 (en) 2024-11-07
RU2020119035A (ru) 2021-12-10
AR114140A1 (es) 2020-07-29
KR102747348B1 (ko) 2024-12-31
EP4431094A2 (en) 2024-09-18
DK3706724T3 (da) 2024-10-14
ES2989706T3 (es) 2024-11-27
CN111328279B (zh) 2023-04-14
IL274414B2 (en) 2024-08-01
KR20200086285A (ko) 2020-07-16
BR112020009171A2 (pt) 2020-11-03
JP2023112076A (ja) 2023-08-10

Similar Documents

Publication Publication Date Title
IL268697A (en) Formulations
EP3722358A4 (en) COMPOSITION
DK3688162T3 (da) Formuleringer
EP3534968A4 (en) ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
DK3697376T3 (da) Sammensætning
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3655017T3 (da) Farmaceutisk sammensætning
EP4125815A4 (en) Therapeutic compositions
EP4234657C0 (en) Compositions
EP3554470A4 (en) COSMETIC COMPOSITIONS
PL3706724T3 (pl) Doustne kompozycje ryfamycyny sv
EP3579971A4 (en) CATALYST COMPOSITIONS
EP3669854A4 (en) PHOTOPOLYMERISABLE DENTAL COMPOSITION
DK3583943T3 (da) Farmaceutisk sammensætning
PT3765379T (pt) Composições
EP3397352A4 (en) DESODRATING COMPOSITIONS
EP3682862A4 (en) CURABLE DENTAL COMPOSITION
HUE063178T2 (hu) Kopanlizib formulációi
DK3528791T3 (da) Dispergible sammensætninger
IL272167A (en) Hemopexin formulations
SMT202400478T1 (it) Composizione farmaceutica
EP3829532A4 (en) KERATIN COMPOSITIONS
EP3675653C0 (fr) Composition antimycotoxine
DK3609464T3 (da) Xanthohumolbaserede sammensætninger
EP3515571A4 (en) Isotopic compositions